Yipinhong subsidiary’s Dexmedetomidine Hydrochloride Injection obtains registration certificate
June 11, 2025
Source: drugdu
50
June 9, Poinsettia(300723) issued an announcement that the company's wholly-owned subsidiary Guangzhou Yipinhong Pharmaceutical Co., Ltd. recently obtained the "Drug Registration Certificate" for Dexmedetomidine Hydrochloride Injection approved and issued by the State Food and Drug Administration.
This drug is a Class 3 chemical drug and is mainly used for sedation during endotracheal intubation and mechanical ventilation in surgical patients undergoing general anesthesia, as well as sedation in intensive care patients. Continuous infusion should not exceed 24 hours.
In the first quarter of 2025, Yipinhong achieved revenue of 377 million yuan and net profit attributable to shareholders of the parent company of 56.59 million yuan.
https://finance.eastmoney.com/a/202506093425539592.html
Copyright©2025 Ddu. All rights reserved.
Read more on
- The marine economy is facing significant policy benefits, and the industrial chain is expected to continue to benefit; Two departments propose 16 measures to support the high-quality development of innovative drugs – “Investment Early Participation” July 3, 2025
- Earwax Secretions May Help Detect Parkinson’s Disease July 3, 2025
- IBS Rates Nearly Doubled During the Pandemic July 3, 2025
- Kangtai Biological’s 13-valent pneumococcal vaccine obtains Türkiye’s GMP certificate and related products are expected to enter the local market July 3, 2025
- Zhifei Biotech has obtained another invention patent certificate July 3, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
